Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (1698)	1/14/1998 9:24:00 PM
From: Anaxagoras	Read Replies (1) \| Respond to of 7041

Hee, hee, heeeeee..... This is rich. <<[Touts are] claiming that Schering-Plough would not have given Zonagen money if they didn't beleive [sic] in Vasomax...Schering-Plough's in-house scientists did not study Vasomax....>> Well, I'm not sure to whom you are referring, but I for one am not claiming this. The point I made and by which I stand is that I find it incredible (in the strictest, most literal sense of the word) that SGP would have given Zonagen millions of bucks without even knowing the ingredients of Vasomax. Do you understand the difference between what I'm claiming and what you reported and why this difference is important? The most recent attack on Vasomax has centered on the composition of Vasomax as though the knowledge of the mere list of ingredients is sufficient for knowledge that the product couldn't possibly work in a manner consistent with reported testing results. If this were true, then don't you think it would have been obvious to SGP that the product was a joke? You claim that SGP didn't study Vasomax in-house- indeed, they did not carry out trials. However, don't you think they at least knew the ingredients of Vasomax? Heck, as Asensio reports, it's publicly available. Or are you actually supposing that SGP is full of a bunch of clowns the silliest of which came to Texas in a tiny yellow Volkswagen (along with three other major pharms, all of whom made comparable offers, as per the most recent CC), and plunked down a few million $ without even bothering to look at the ingredients of the product? And that even after looking at the ingredients, which some apparently think a priori couldn't possibly work, the tall thin driver with the green hair and red nose said, in his most whacky of voices, to the short, fat guy with the purple oversized shoes: "Emmmm, couldn't possibly woik- but give 'em the suitcase o' cash from the back seat so that the ride home will be more comfy- Joe, my knees is a keeeeeeeeellin' me!!!" Of course I may be wrong, and I'm willing to listen, but trading from the long side in the mean time.... Anaxagoras

To: Bill Wexler who wrote (1698)	1/15/1998 9:30:00 AM
From: Linda Kaplan	Read Replies (3) \| Respond to of 7041

Headline: Asensio & Co.: Zonagen's Vasomax Fast-Acting Claims Proven False and Fraudulent ====================================================================== NEW YORK, Jan. 15 /PRNewswire/ -- Asensio & Co. today issued the following: Zonagen Inc. (OTC-Bulletin Board: ZONA) claims its 40 mg phentolamine pills are effective in treating male erectile dysfunction ("MED") because of Vasomax's secret, new, fast acting formulation. Specifically, Zonagen claims that it is Vasomax's fast action that causes Vasomax to work as a MED treatment. These claims are false and completely absurd. First, Zonagen's Vasomax patent application proves definitively that Vasomax contains nothing secret or new. Nor is Vasomax mixed or manufactured in any new way. Secondly, Vasomax is not fast acting. In fact, even accepting Zonagen's own test results, Vasomax is by every measure much slower acting than standard phentolamine. Doctors R. Imhof, B. Garnier, L. Brunner, G. Keller and T. Roher conducted a study titled "Human Pharmacology of Orally Administered Phentolamine." The study was published as part of the Phentolamine Workshop and Symposium held in London, England in November 1975. The investigations were performed in collaboration with the Pharmacological Chemistry Section of Ciba-Geigy in Basle and Paris. The objective of this detailed human-pharmacology study was to measure the blood concentration and the excretion of orally administered phentolamine. A comparison of this study and the Zonagen claims shows that regular phentolamine is far more fast acting than Vasomax. Regular phentolamine reached a maximum blood concentration of 33 ng/ml in 30 minutes. Vasomax claims a level of 16.7 ng/ml in 30 minutes. Regular phentolamine reached a blood concentration of over 20 ng/ml in 15 minutes. Vasomax claims a level of 6.3 ng/ml in 15 minutes. Regular 45-year-old oral phentolamine reaches much higher concentrations, much faster than Vasomax. In fact, standard phentolamine's maximum concentration was more than twice that claimed by Zonagen for its fast acting Vasomax formulation. The contents of the Vasomax patent application already prove that Zonagen has done nothing to phentolamine that in any way reformulates or changes the pharmacology of phentolamine. The Imhof study provides even more direct and specific proof that Zonagen's fast acting reformulation claims are entirely false and untrue. SOURCE Asensio & Company, Inc. -0- 01/15/98 /CONTACT: Manuel Asensio of Asensio & Company, 212-702-8800/